(secondQuint)Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids.

 This is a phase 1A/1B study.

 Phase 1A is designed to determine the maximal tolerated dose (MTD) and toxicity of ridaforolimus in combination with paclitaxel and carboplatin in patients with advanced or recurrent solid tumors.

 The MTD determined in this study will be the recommended dose to study in the phase 1B or in future phase 2 trials.

.

 Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids@highlight

The purpose of this study is to: - Test the safety of a new investigational drug called MK-8669 (ridaforolimus) - Determine the maximum tolerated dose of MK-8669 - Determine the effectiveness of the maximum tolerated dose of MK-8669